Oncology Data Advisor

i3 Health

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

  1. hace 5 d

    Clinical Trial Enrollment Barriers: Awareness Isn’t the Same as Access

    Check out the full article at: https://oncdata.com/oncology-unfiltered-clinical-trial-enrollment-barriers While clinical trials represent the cutting edge of modern cancer therapy, significant disparities persist in determining who actually enrolls in them. In this episode of Oncology Unfiltered, Melissa Cotrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sat down with Editor in Chief Matthew Hadfield, DO, Medical Oncologist and Assistant Professor of Medicine at Brown University Legorreta Cancer Center, to unpack the practical, structural, and clinical hurdles that prevent eligible patients from accessing potentially lifesaving investigational therapies. Together, they explore how the oncology community can translate trial availability into meaningful access.

    Clinical Trial Enrollment Barriers: Awareness Isn’t the Same as Access

  2. 11 ago

    Building Trust in Real-World Evidence With AI and High-Quality Data

    Read the full article at: https://oncdata.com/real-world-evidence-ai-in-oncology Artificial intelligence (AI) is rapidly transforming oncology research, but its impact depends on high-quality data. As researchers increasingly rely on real-world evidence (RWE) to complement clinical trials, ensuring that data is accurate, complete, and transparent has become just as important as developing new AI tools. In this episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Saamir Pasha, Senior Biostatistician at Ontada, about two complementary areas of innovation—the establishment of rigorous frameworks to assess the quality of oncology real-world data, and the exploration into how generative AI can accelerate complex biostatistical workflows while maintaining scientific rigor and regulatory transparency. Together, these efforts illustrate how AI is poised to enhance—not replace—the expertise required to generate reliable evidence in oncology.

    Building Trust in Real-World Evidence With AI and High-Quality Data

  3. 10 ago

    One Size Fits One: Personalizing Cancer Prevention Through AI-Enhanced Imaging

    Read the full article at: https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.

    One Size Fits One: Personalizing Cancer Prevention Through AI-Enhanced Imaging

  4. 10 ago

    AI-Driven Pathological Subtyping for Pancreatic Cancer: Moving From Promise to Practical Application

    Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains inconsistent. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights the critical shift that is moving AI from theoretical promise to practical application.

    AI-Driven Pathological Subtyping for Pancreatic Cancer: Moving From Promise to Practical Application

  5. 30 jul

    Advancing Extrapulmonary NEC: DLL3 & Beyond

    Are you treating extrapulmonary neuroendocrine carcinomas based on where they start—or what they actually are? In this faculty follow-up to their i3 Health activity (Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets), Andrew Hendifar, MD, and Danielle Hutchings, MD (Cedars-Sinai Medical Center), unpack why treating these rare, aggressive tumors according to site of origin rather than tumor lineage can compromise outcomes. They clarify crucial pathologic distinctions between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) while emphasizing the essential role of multidisciplinary collaboration in precision care. The experts also explore the novel therapeutic landscape of delta-like ligand 3 (DLL3)–targeted therapies, highlighting the promise of DLL3 T-cell engagers in extrapulmonary disease. They address ongoing diagnostic hurdles—such as standardized immunohistochemistry (IHC) expression thresholds and expanding send-out testing access—while sharing key insights on emerging clinical trials evaluating T-cell engager monotherapies and chemo-immunotherapy combinations. Claim your CME credit: bit.ly/488fPhK Download and review the companion Clinical Challenges in Extrapulmonary NEC Slide Deck: bit.ly/4w2Pni3

    Advancing Extrapulmonary NEC: DLL3 & Beyond

  6. 28 jul

    Prostate Cancer Breakthroughs: TALAPRO-3, PROTEUS, & Earlier Therapy

    What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies? In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO that is actively reshaping care algorithms across the prostate cancer continuum. Dr. Freedland dives into the breakthrough TALAPRO-3 trial—exploring why talazoparib plus enzalutamide is making waves across diverse HRR alterations (including BRCA and ATM)—and analyzes how the PROTEUS trial’s 35% reduction in subsequent salvage therapies could redefine surgical planning for high-risk localized disease. Plus, get an insider's look at what’s on the horizon with PSMA PET imaging, T-cell engagers, and AR degraders. 🎓Complete the Educational Activity: https://bit.ly/4x2BnWf

    Prostate Cancer Breakthroughs: TALAPRO-3, PROTEUS, & Earlier Therapy

  7. 28 jul

    Advances in CIDP: Consensus Definitions, Emerging Pipeline & Individualized Care

    Chronic inflammatory demyelinating polyneuropathy (CIDP) presents significant challenges in both diagnosis and long-term disease management. As consensus definitions, emerging targeted therapies, and research into serologic biomarkers evolve, how can clinicians optimize individual care algorithms? In this follow-up discussion, Karissa Gable, MD, Duke University Medical Center, breaks down recent breakthroughs in CIDP care and trial design: - Standardizing CIDP Terminology: Key updates from the new international consensus definitions paper establishing unified criteria for disease remission, stability, treatment response, and refractory disease. - The Emerging Pipeline: What’s next in therapeutic development, including FcRn antagonists (nipocalimab and batoclimab) and complement inhibitors. - Shared Decision-Making: Practical strategies for tailoring therapy selection based on patient preferences, lifestyle, comorbidities, and administration routes. - Building Confidence in CIDP Care: Applying 2021 EAN/PNS guidelines to navigate diagnosis and ongoing treatment adjustments when first-line options fall short. 💡 Complete the Educational Activity: https://bit.ly/4pPcVWe 👉 Access the accompanying slide deck for comprehensive guidance on CIDP detection and management: https://bit.ly/4pPcVWe

    Advances in CIDP: Consensus Definitions, Emerging Pipeline & Individualized Care

  8. 9 jul

    Information Overload and the Portal Patient: The Era of Instant Test Results

    Read the full article here: https://oncdata.com/information-overload-and-the-portal-patient The way that patients receive medical information has changed dramatically. Through electronic health record portals, laboratory values, imaging reports, and pathology results often become available the moment they are finalized—sometimes before a physician has had the opportunity to review or discuss them. While this unprecedented access promotes transparency and patient engagement, it also creates new challenges for communication, trust, and anxiety management. In the latest episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, to explore how instant access to test results is reshaping oncology care.

    Information Overload and the Portal Patient: The Era of Instant Test Results
Ver todo (447)

Información

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Ficha técnica

  • Creado por
    i3 Health
  • Años en activo
    2014 - 2026
  • Episodios
    447
  • Clasificación
    Apto
  • Derechos de autor
    © All rights reserved
  • Sitio web del podcast
    Oncology Data Advisor